Theodore J. Boritzki

Author

General Atomics (United States)

Also Known As

Boritzki, Theodore, T J Boritzki, T. BORITZKI, T. J. Boritzki, T.J. Boritzki, Theodore Boritzki, Theodore J. Boritzki

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

General Atomics (United States)Warner University Indiana University – Purdue University Indianapolis Agouron Institute University of Auckland

About

Theodore J. Boritzki is an author at General Atomics (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	896
2	Biochemistry	12	13	768
3	Natural Sciences	10	10	514
4	Health Sciences	2	2	137
5	Engineering	1	1	50

Theodore J. Boritzki

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis, and X-ray Cocrystal Structure Stacie S. Canan Koch, Lars Thoresen, Jayashree Tikhe, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryParp-1 ProteinChemical BiologyPolymerase-1 Inhibitors	2002	134
Inhibition of type II topoisomerase by fostriecin Theodore J. Boritzki, Tammy S. Wolfard, Judith A. Besserer, Biochemical Pharmacology Type Ii TopoisomeraseMedicinePharmacologyInhibitory ActivityDrug Discovery	1988	118
Purine and pyrimidine nucleotide patterns of normal, differentiating, and regenerating liver and of hepatomas in rats. Robert Jackson, May S. Lui, Theodore J. Boritzki, PubMed Hepatic DisordersHepatotoxicityMetabolismPyrimidine NucleotidesNormal Rat Liver	1980	104
Biochemical pharmacology of the lipophilic antifolate, trimetrexate Robert Jackson, David W. Fry, Theodore J. Boritzki, Advances in Enzyme Regulation Molecular PharmacologyMedicinal ChemistryBiochemical PharmacologyPharmaceutical SciencePharmacological Study	1984	94
AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies S. E. Webber, Charlotte A. Bartlett, Theodore J. Boritzki, Cancer Chemotherapy and Pharmacology Medicinal ChemistryVivo Preclinical StudiesBiochemistryNatural SciencesImmunology	1996	89
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Christopher Calabrese, Michael A. Batey, Huw D. Thomas, PubMed Pharmaceutical ScienceChemoprevention StrategyPharmacotherapyPolymerase-1 InhibitorsPotent Nontoxic Poly	2003	79
DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard Trudi A. Gourdie, Kisione K. Valu, G. Lance Gravatt, Journal of Medicinal Chemistry	1990	78
AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase Theodore J. Boritzki, Charlotte A. Barlett, Cathy Zhang, Investigational New Drugs BiochemistryGlycobiologyOligonucleotideGlycinamide Ribonucleotide FormyltransferaseGlycosylation	1996	62
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro Amy K. Patick, Theodore J. Boritzki, Laird Bloom Antimicrobial Agents and Chemotherapy ImmunologyAntiviral DrugImmunotherapyNelfinavir MesylateDrug Resistance	1997	58
In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles) David W. Fry, Theodore J. Boritzki, Judith A. Besserer, Biochemical Pharmacology Medicinal ChemistryNucleic Acid ChemistryEngineeringNucleic Acid SynthesisNatural Sciences	1985	50

Page 1